Your browser doesn't support javascript.
loading
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).
Day, Fiona; Sridharan, Swetha; Lynam, James; Gedye, Craig; Johnson, Catherine; Fraser, Allison; Thompson, Stephen R; Michael, Michael; Leong, Trevor; Roy, Amitesh; Kumar, Mahesh; van der Westhuizen, Andre; Quah, Gaik T; Mandaliya, Hiren; Mallesara, Girish; Sappiatzer, Joshua; Oldmeadow, Christopher; Martin, Jarad.
Affiliation
  • Day F; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia. fiona.day@calvarymater.org.au.
  • Sridharan S; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia. fiona.day@calvarymater.org.au.
  • Lynam J; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. fiona.day@calvarymater.org.au.
  • Gedye C; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
  • Johnson C; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Fraser A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Thompson SR; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
  • Michael M; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Leong T; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
  • Roy A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Kumar M; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
  • van der Westhuizen A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Quah GT; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
  • Mandaliya H; Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Mallesara G; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Sappiatzer J; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Oldmeadow C; Flinders Medical Centre, Bedford Park, Adelaide, SA, Australia.
  • Martin J; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
BMC Cancer ; 22(1): 1324, 2022 Dec 17.
Article in En | MEDLINE | ID: mdl-36528772
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Carcinoma / Deglutition Disorders Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: Oceania Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Carcinoma / Deglutition Disorders Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: Oceania Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication: